• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

S2. Ep 56: Insights from a Pharmacy Times Peer Exchange: How to Talk the Talk

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Experts share insights on patient discussions and side effect management strategies in HER2 breast cancer. Read More

Expert Q&A: Pharmacist-Led Strategies to Improve Cholesterol Management

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Amanda Gronniger, PharmD, CPh, BCCP discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies. Read More

Camber Pharmaceuticals Announces Addition of Olmesartan Medoxomil Tablets, USP

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

From MGUS to Myeloma: Understanding and Interrupting Disease Progression

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases. Read More

Darolutamide Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial. Read More

June-July 2025: Upcoming NCPA Items for Pharmacy Teams

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT